{
    "id": 1305,
    "fullName": "NTRK1 rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK1 rearrangement indicates an unspecified rearrangement of the NTRK1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4914,
        "geneSymbol": "NTRK1",
        "terms": [
            "NTRK1",
            "MTC",
            "p140-TrkA",
            "TRK",
            "Trk-A",
            "TRK1",
            "TRKA"
        ]
    },
    "variant": "rearrange",
    "createDate": "08/06/2014",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6725,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in objective response in 75% (3/4) of patients with advanced solid tumors harboring rearrangement in NTRK1, NTRK2, or NTRK3 genes (AACR Apr 2016, Abstract # CT007).",
            "molecularProfile": {
                "id": 1328,
                "profileName": "NTRK1 rearrange"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5790,
                    "pubMedId": null,
                    "title": "Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-na\u00efve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=4abd89d1-63f0-4e65-b91c-486888d54e7a&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1328,
            "profileName": "NTRK1 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}